A Comparison for Liver Cancer Treatment Alternatives

Musa, Musa Sani; Ozsahin, Dilber Uzun; Ozsahin, Ilker

doi:10.1109/icaset.2019.8714471

Cited by 9 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Basically, our results regarding relevant attributes for liver cancer therapies align with previous findings that the attributes concerning overall survival are most important (e.g., 2 ), followed by attributes concerning risk of side effects and adverse events 2 . Additionally, we found that attributes regarding treatment time, comfortability, and administration are also considered relevant, which supports findings from Chiba et al 40 , Lo et al 2 , and Musa et al 35 . However, we found that attributes related to costs of therapies, which Musa et al 35 considered relevant, were less important.…”

Section: Discussionsupporting

confidence: 90%

“…Additionally, we found that attributes regarding treatment time, comfortability, and administration are also considered relevant, which supports findings from Chiba et al 40 , Lo et al 2 , and Musa et al 35 . However, we found that attributes related to costs of therapies, which Musa et al 35 considered relevant, were less important.…”

Section: Discussionsupporting

confidence: 90%

“…For example, Li et al 33 , Lo et al 2 , and Puts et al 34 reported overall survival was the most important, followed by the risk of side effects and adverse events 2,34 . Other categories considered relevant in the studies are costs 35 , treatment time [36][37][38] , comfortability 39 , and administration 2,[36][37][38]40 . Based on the categories we preselected this way, we determined 14 specific clinical attributes, presented in Table 1, being careful to ensure that patients, physicians, and medical laymen could evaluate them.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Identification of Relevant Attributes for Liver Cancer Therapies (IRALCT): a maximum-difference-scaling analysis

Hensen

Winkelmann

Wacker

et al. 2022

Sci Rep

View full text Add to dashboard Cite

The Identification of Relevant Attributes for Liver Cancer Therapies (IRALCT) project is intended to provide new insights into the relevant utility attributes regarding therapy choices for malignant primary and secondary liver tumors from the perspective of those who are involved in the decision-making process. It addresses the potential value of taking patients’ expectations and preferences into account during the decision-making and, when possible, adapting therapies according to these preferences. Specifically, it is intended to identify the relevant clinical attributes that influence the patients’, medical laymen’s, and medical professionals’ decisions and compare the three groups’ preferences. We conducted maximum difference (MaxDiff) scaling among 261 participants (75 physicians, 97 patients with hepatic malignancies, and 89 medical laymen) to rank the importance of 14 attributes previously identified through a literature review. We evaluated the MaxDiff data using count analysis and hierarchical Bayes estimation (HB). Physicians, patients, and medical laymen assessed the same 7 attributes as the most important: probability (certainty) of a complete removal of the tumor, probability of reoccurrence of the disease, pathological evidence of tumor removal, possible complications during the medical intervention, welfare after the medical intervention, duration and intensity of the pain, and degree of difficulty of the medical intervention. The cumulative relative importance of these 7 attributes was 88.3%. Our results show that the physicians’, patients’, and medical laymen’s preferences were very similar and stable.Trial registration DRKS-ID of the study: DRKS00013304, Date of Registration in DRKS: 2017/11/16.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 90%

mentioning

confidence: 99%

See 1 more Smart Citation

Identification of Relevant Attributes for Liver Cancer Therapies (IRALCT): a maximum-difference-scaling analysis

Hensen

Winkelmann

Wacker

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…This is the process of increasing or stimulating the immune system to fight against potential cancer cells or tumor cells in the body [4]. This can be achieved through the administration of immune-enhancing vaccines, monoclonal antibodies, therapeutic agents (drugs), cytokines, lymphocytes, or other biological immune modifiers used to increase or activate the immune system to promote an effective response against tumors [27]. This offers a long-lasting control for tumor cells without any chances of recurrence.…”

Section: Immunotherapymentioning

confidence: 99%

“…It is often more targeted than other conventional methods of treating cancer cells. This can lead to an overstimulated or misdirected immune response which may cause a severe attack on other organs or fatal allergic reactions [4], [27], [35]- [40].…”

Section: Immunotherapymentioning

confidence: 99%

Hydrogel-Based Drug Delivery Nanoparticles with Conventional Treatment Approaches for Cancer Tumors; A comparative study using MCDM Technique

Onakpojeruo¹,

Uzun

Ozsahin

2022

Preprint

Self Cite

View full text Add to dashboard Cite

Cancer is a disease caused by the uncontrolled division of abnormal cells in a part of the body leading to cell damage or death (Apoptosis). This could result in the death of the host carrier. Most death cases of cancer patients have been linked to the systematic administration of therapeutic agents (chemotherapy) and other conventional methods as the preferred treatment approach for cancer therapy. This treatment mortality is associated with side effects, off-target accumulation, toxicity, and rapid renal and hepatic clearance. In recent times, scientists have researched on targeting tumor sites and enhanced retention of constant drug delivery to tumors to mitigate side effects, and toxicity-related challenges. Water-containing polymers called Hydrogels is a unique discovery by scientist and researchers for highly effective drug delivery systems for cancer therapy. Drugs loaded into these hydrogels remain relatively stable owing to the network-like structure and organic tissue-like consistency of these drug delivery systems. This study is focused on comparing hydrogel-based drug delivery systems with other conventional methods of cancer therapy using the Multicriteria decision-making (MCDM) method called fuzzy Preference Ranking Organization Method for Enrichment Evaluations (PROMETHEE). The comparison is based on certain criteria and assigned weights of importance. The results from this study indicate that hydrogel-based therapy with a net flow of 0.1457 is the most favorable and optimum therapeutic approach for the general treatment of cancer diseases. Followed by surgery with a net flow of 0.1415, and hydron therapy, immunotherapy, and radiation therapy came third, fourth, and fifth with net flows of 0.0489, -0.0858, and -0.1062, respectively. Chemotherapy with a net flow of -0.1441 was the least ranked alternative. This study demonstrates that the approach taken will be beneficial and supportive in providing answers for healthcare decision-makers who are dealing with uncertainty issues and that it can be enhanced with the availability of more alternatives, and criteria, and by assigning weights of importance to the specific conditions of the individual cancer patients.

show abstract